For the quarter ending 2026-03-31, TMCI had -$1,164K decrease in cash & cash equivalents over the period. $4,178K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Provision for allowance for credit losses | - | - | -69 | 581 |
| Net loss | -17,961 | -9,394 | -16,288 | -33,320 |
| Depreciation and amortization expense | 899 | 2,808 | 2,778 | 5,037 |
| Provision for allowance for credit losses | 112 | 834 | - | - |
| Share-based compensation expense | 8,034 | 7,555 | 7,998 | 18,270 |
| Non-cash lease expense | 571 | 533 | 556 | 1,133 |
| Amortization of debt issuance costs | 262 | 69 | 75 | 148 |
| Debt extinguishment loss | - | 2,737 | - | - |
| Amortization (accretion) of premium (discount) on marketable securities, net | -5 | 4 | 5 | 114 |
| Other Noncash Income Expense | -587 | -458 | -531 | -219 |
| Accounts receivable | -11,685 | 9,518 | 2,557 | -9,985 |
| Inventory | 335 | -5,393 | -973 | 3,142 |
| Prepaid expenses and other assets | -608 | -697 | 615 | -84 |
| Other non-current assets | 293 | 200 | -62 | 365 |
| Operating lease liabilities | -854 | -825 | -829 | -1,553 |
| Accounts payable | 6,811 | -9,377 | -3,856 | 9,437 |
| Accrued liabilities | -3,126 | 778 | 2,118 | -5,309 |
| Increase Decrease In Other Operating Capital Net | -235 | 58 | -36 | -57 |
| Net cash provided by (used in) operating activities | 7,240 | -8,026 | -9,092 | 1,148 |
| Purchases of available-for-sale marketable securities | 16,071 | 5,682 | 4,640 | 30,249 |
| Sales and maturities of available-for-sale marketable securities | 11,317 | 17,746 | 16,185 | 33,408 |
| Purchases of property and equipment | 3,062 | 2,398 | 2,809 | 8,310 |
| Acquisition, net of cash acquired | - | 0 | - | - |
| Net cash provided by (used in) investing activities | -7,816 | 9,666 | 8,736 | -5,151 |
| Proceeds from interest bearing term debt | - | 59,310 | - | - |
| Proceeds from insurance premium financing | - | 0 | 570 | 983 |
| Debt issuance costs | 6 | 1,199 | - | - |
| Payments on interest bearing term and revolving debt | - | 56,315 | - | - |
| Payments on insurance premium financing | 466 | 409 | 409 | 98 |
| Proceeds from issuance of common stock from public offering, net of issuance costs and underwriting discount of 7.5 million | - | 0 | - | - |
| Proceeds from exercise of employee stock options | 91 | 70 | 241 | 235 |
| Taxes from withheld shares | 207 | 75 | 412 | 415 |
| Net cash provided by (used in) financing activities | -588 | 1,382 | -10 | 705 |
| Net increase (decrease) in cash and cash equivalents | -1,164 | 3,022 | -366 | -3,298 |
| Cash and cash equivalents at beginning of period | 10,708 | 7,686 | 11,350 | - |
| Cash and cash equivalents at end of period | 9,544 | 10,708 | 7,686 | - |
TREACE MEDICAL CONCEPTS, INC. (TMCI)
TREACE MEDICAL CONCEPTS, INC. (TMCI)